Watson Can Sell Generic Actos Now, U.S. Judge Rules
This article is for subscribers only.
Watson Pharmaceuticals Inc. may begin immediately marketing a generic version of Takeda Pharmaceutical Inc.’s diabetes drug Actos, a federal judge ruled, handing the U.S. Food and Drug Administration a defeat.
U.S. District Judge Amy Berman Jackson in Washington today overturned an FDA decision that kept Watson from joining a period of shared exclusivity granted to the companies that are first to file for the right to market generic versions of branded drugs. Actos is the world’s top-selling diabetes medicine.